Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xcell Biosciences

Explore full profile

Building products that enable propagation and gene editing in challenging cell types for clinical research and cell therapy applications

San Francisco, United StatesFounded 2012Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2022
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Xcell Biosciences and the history behind them.

About Xcell Biosciences

Xcell Biosciences, based in San Francisco, is a pioneering life science startup focused on advancing cell therapy manufacturing. The company develops cutting-edge systems that enable precise control over primary cell phenotype and function, which is crucial for optimizing the efficacy and persistence of cell therapies. Xcell Biosciences serves clients in the biotechnology and pharmaceutical sectors, particularly those involved in cell therapy research and development. Operating in the highly specialized market of cell therapy, the company employs a business model centered around the sale and licensing of its proprietary technology. Revenue is generated through direct sales of their systems, as well as through partnerships and collaborations with other biotech firms.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2012
Headquarters
San Francisco, United States
Employees
17
Open positions
None listed
Dealroom signal
61.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
b2b
Links
WebsiteLinkedInX

Latest news

Press, funding announcements and product moves mentioning Xcell Biosciences.

See all news

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Apr 2024 $0 — LabCorp ↗
SERIES BOther financing Jan 2022 $28M $110M LabCorp · Viking Global Investors · Casdin Capital · Dynamk Capital ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Xcell Biosciences website traffic

Latest recorded traffic for Xcell Biosciences is 1.6K monthly website visits, down 27.3% over the last three months. Xcell Biosciences's team declined 41.4% over the past year.

Latest monthly visits1.6K 3-month web change-27.3% 1-year team growth-41.4%
Monthly website visitsOct 2017–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Ikena OncologyPatient-directed oncology therapies across pathways relevant in tumor and immune cells Boston, United States Acquired 12 $324M $629M
ApollomicsAn innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies Pleasanton, United States Operational
Tizona TherapeuticsTransforming cancer treatment with first-in-class immunotherapies driven by novel scientific insights South San Francisco, United States Operational
Viracta TherapeuticsViracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients Encinitas, United States Operational
Adicet BioA biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer Redwood City, United States Operational
ImmuneedDeveloping a new generation of prostate cancer vaccines, based on activation of the body's own immune system Uppsala kommun, Sweden Acquired
Akamis BioLeading company in developing cancer gene therapies Abingdon, United Kingdom Operational
EltheraBringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs Schlieren, Switzerland Operational
Showing 8 of the closest matchesCompare every metric →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Series A6 investors entered at this stage

  • HBM Genomics
  • HBM Healthcare Investments
  • Casdin Capital
  • LabCorp
  • Dynamk Capital
  • Formic Ventures

Other known investors3 additional known investors

  • Berkeley Lab
  • Berkeley SkyDeck Accelerator
  • University of California, Berkeley

Talent

Book a demo to see the people
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States95.7%
🇧🇷 Brazil4.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xcell Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xcell Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.